Taxol Carboplatin and Erythropoetin
Time to progression (physical examination and radiologic imaging
Ovarian Cancer
DRUG: Paclitaxel
Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25%, Time to progression, every 3 months for up to 3 years
Toxicity, defined as hematological and non-hematological adverse events of grade \>= grade 1, after every cycle during therapy phase and after every 3 months during follow-up, for up to 3 years
Time to progression (physical examination and radiologic imaging